.png)
Phenytoin Genotyping
Why Get Tested?
To determine the concentration (Severe Cutaneous Adverse Reactions) of
carbamazepine in the blood to establish an appropriate dose and maintain
a therapeutic level.
Why Get Tested? To determine the concentration (Severe Cutaneous Adverse Reactions) of carbamazepine in the blood to establish an appropriate dose and maintain a therapeutic level.
Also known as: HLA-B*1502
Description: Carbamazepine is an anticonvulsant drugs are widely used for convulsive disorder, like epilepsy, partial seizures, generalized tonic-clonic seizures and mixed seizures. For a better control of such symptom and severity, patients need to start prolong therapy with a specific dose with a well prescribed dosages regiment by physician. Clinical studies have demonstrated associations between human leukocyte antigen (HLA) genotypes and drug-induced adverse skin reactions for this drugs. The presence of the HLA-B*1502 allele increases the risk of developing toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome (SJS). The frequency of the HLA-B*1502 allele, throughout Asia: 10% to 15%, 2% to 4% frequency in Southeast Asians, including Indians. The FDA recommends that individuals of Asian ancestry be genotyped for the presence of the HLA-B*1502 allele prior to receiving Carbamazepine, Phenytoin, lamotrigine, and oxcarbazepine.
Reasons for Referral: Epilepsy, Neuropathy, partial seizures, generalized tonic-clonic seizures and mixed seizures.
Sample Requirement: Whole EDTA blood
Test Preparation: No test preparation is needed.
Test Done by The PCR product is then separated by gel electrophoresis